Children who receive cisplatin as part of their cancer treatment are at risk for progressive and/or permanent hearing loss as a result of their treatment.
Survivorship Matters Blog By CAC2 Individual Member Mary Beth Collins “Your child has to be alive to experience side effects” It is heard by every
Assorted News from the Last Week: CAC2 Member Mary Beth Collins explains the importance of the new FDA approval of Pedmark: “With the FDA’s recent
By CAC2 Individual Member Joe Baber Because of my grandson, Conor, a neuroblastoma survivor, I have met so many people in our childhood cancer community
Assorted News from the Last Week: CAC2 Member Joe Baber reflects on the Gabriella Miller Kids First 2.0 legislation pending in Congress: “We’re all thankful
This month, Dr. Gregory Reaman was named by the Childhood Cancer Data Initiative (CCDI) as the new Scientific Director. In this role, Dr. Reaman will
Blogged with permission and thanks by the ACCELERATE Fit for Filing Working Group The ACCELERATE PLATFORM’S Fit for Filing (FFF) group was formed in 2019 to explore
Assorted News from the Last Week: The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (AVE-PC) in pediatric
Assorted News from the Last Week: November is National Family Caregivers Month. The President Joe Biden honored family caregivers for all they do for the
The U.S. Food and Drug Administration issued a draft guidance that, when finalized, will provide the agency’s perspective on the ethical considerations for including and
